In contrast, the use of iron chelating agents can inhibit the activity of these kinases, thereby reducing the phosphorylation of tau and APP, demonstrating the potential to slow the progression of AD (Guo et al., 2013a). The gene discussed is MAPT; the disease is Alzheimer disease.